SLGL Stock — Sol-Gel Technologies Ltd.: Cash, EV, Pipeline

What they do

Our principal executive offices are located at 7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650 Israel and our telephone number is 972-8-931 3433. Our website address is http://www.sol-gel.com . We use our website as a channel of distribution company information.

Source: 20-F FY2025 via SEC EDGAR

Share price

$55.21

Market cap

$180.8M

Cash

$11.0M

Enterprise value

$169.8M

Balance sheet

Cash	$11.0M
Debt	$0.0M
Net cash	$11.0M
Enterprise value	$169.8M
Basic shares	2.8M shares
Fully diluted shares	3.0M shares
Fully diluted market cap	$164.6M
Cash per share	$3.97
Quarterly burn	$0.1M
Cash runway	79.6 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-13.

Share structure

Common

2.8M

Pre-funded warrants

0.0M

Options

0.2M

RSUs

—

Warrants

—

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

3.0M

Cap table as of 2025-12-31.

Price history

Loading SLGL daily closes…

Loading price history…

Next catalyst

Patidegib Topical Gel · Now - Dec 24, 2026 Now · Phase 3 · Gorlin Syndrome

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Dec 24, 2026 Now	Patidegib Topical Gel	Phase 3	Gorlin Syndrome	late November 2026

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

SGT-610

Phase 3 · Active Modality: topical gel

Aliases patidegib 2% gel

Target hedgehog pathway

Indications

Gorlin Syndrome (BCC prevention) (Phase 3)

Status note Lead candidate. Phase III clinical study ongoing for prevention of new basal cell carcinomas in adults with Gorlin Syndrome. Orphan Drug Designation and Breakthrough Therapy designation.

SGT-210

Stage not disclosed · Active Modality: topical drug candidate

Aliases erlotinib

Target EGFR

Indications

not disclosed (Stage not disclosed)

Status note Topical erlotinib platform; development continuing. No stage or indication disclosed in 20-F.

Per-asset detail extracted from the 20-F filed 2026-03-19. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Patidegib Topical Gel
Lead indication	Gorlin Syndrome
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06050122	Phase 3	Active, not recruiting	Sponsor	Sol-Gel Technologies, Ltd.	—	Gorlin Syndrome	late November 2026

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Sol-Gel Technologies, Ltd. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Great Point Partners	274,363	no change	4.79%	2026-08-14
Stonepine Capital	14,469	-13,309	0.82%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

SLGL — Sol-Gel Technologies Ltd. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

SLGL — Sol-Gel Technologies Ltd.